Top Markets
#1 NKN NKN +105.45%
#2 Black Phoenix Black Phoenix +99.33%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +25.48%
#5 Saakuru Saakuru +24.37%
#6 Arcblock Arcblock +18.04%
#7 Bedrock Bedrock +15.93%
#8 pippin pippin +11.93%
#9 StakeStone StakeStone +11.42%
#10 Bless Bless +10.89%
Coin of the day
NKN NKN
Settings
Language
ENGLISH
Currency
USD
Theme
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rank in Stocks #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Share Price
$207.15
Market Cap
$366.28B
Change (1 day)
0.99%
Change (1 year)
2.91%
Country
US
Trade AbbVie Inc. (ABBV)

Category

Healthcare
Number of shares outstanding for AbbVie Inc. (ABBV)
Number of shares outstanding as of December 2025: 1.78B
According to AbbVie Inc. latest financial reports and stock price the company's current number of shares outstanding is 1.78B. At the end of December 2024 the company had 1.77B shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for AbbVie Inc. (ABBV) from 2009 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 1.78B -0.57%
2025 1.79B 1.23%
2024 1.77B 0.06%
2023 1.77B -0.17%
2022 1.77B 0.06%
2021 1.77B 6.18%
2020 1.67B 12.56%
2019 1.48B -3.89%
2018 1.54B -3.45%
2017 1.60B -1.60%
2016 1.62B -0.18%
2015 1.63B 1.88%
2014 1.60B 0.38%
2013 1.59B 0.76%
2012 1.58B -2.41%
2011 1.62B 0.00%
2010 1.62B 0.00%
2009 1.62B 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 898.00M -49.56%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 3.10B 74.12%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 2.43B 36.41%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 1.91B 7.45%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 2.49B 39.85%
US